ITRI then-Executive Vice President C.T. Liu (second left), Merck Life Science Global Head of Technology Management of Process Solutions Business Willem Kools (third right) at the press conference.
The global biopharma market is growing rapidly and is estimated to reach USD 278 billion in 2020. To address this trend, ITRI and international pharmaceutical and chemical company Merck signed an MOU on March 26th, announcing the establishment of Taiwan-Merck Biopharma R&D & Training Collaboration Program at ITRI Guangfu Innovation Campus in Hsinchu. The collaboration program will officially launch in May. This project is expected to strengthen Taiwan’s biopharma sector by combining the R&D resources from ITRI with key technologies and advanced manufacturing processes from Merck to cultivate high-end professionals in Taiwan. The collaboration aims to enhance Taiwan’s biopharma production competence, expand the global market share of its biopharma industry, and create new business opportunities in precision medicine.